keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis b phases

keyword
https://www.readbyqxmd.com/read/29352124/hbv-infection-potentiates-resistance-to-s-phase-arrest-inducing-chemotherapeutics-by-inhibiting-chk2-pathway-in-diffuse-large-b-cell-lymphoma
#1
Xinying Zhao, Xudong Guo, Libo Xing, Wenqin Yue, Haisen Yin, Miaoxia He, Jianmin Wang, Jianmin Yang, Jie Chen
A considerable number of diffuse large B-cell lymphoma (DLBCL) patients are infected with hepatitis B virus (HBV), which is correlated with their poor outcomes. However, the role of HBV infection in DLBCL treatment failure remains poorly understood. Here, our data demonstrated that HBV infection was closely associated with poorer clinical prognosis independent of its hepatic dysfunction in germinal center B-cell type (GCB type) DLBCL patients. Interestingly, we found that DLBCL cells expressing hepatitis B virus X protein (HBX) did not exhibit enhanced cell growth but did show reduced sensitivity to methotrexate (MTX) and cytarabine (Ara-C), which induced S-phase arrest...
January 19, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29343454/rational-design-and-evaluation-of-hbsag-polymeric-nanoparticles-as-antigen-delivery-carriers
#2
Hitesh Kumar Dewangan, Tarun Pandey, Lakshmi Maurya, Sanjay Singh
The present work is focused on the development and evaluation of single dose sustained-release Hepatitis B surface antigen (HBsAg) loaded nanovaccine for Hepatitis B. The conventional treatment suffers from repeated administration and hence requires a booster dose. Therefore, polymeric nanovaccine of HBsAg was developed by double emulsion solvent evaporation technique, utilizing central composite design for formulation optimization. The effects of independent variables (like polymer amount, stabilizer concentration, aqueous/organic phase ratio and homogenizer speed) were also studied on critical quality attributes like particle size and entrapment efficiency...
January 14, 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29342849/comparative-response-of-the-hepatic-transcriptomes-of-domesticated-and-wild-turkey-to-aflatoxin-b%C3%A2
#3
Kent M Reed, Kristelle M Mendoza, Juan E Abrahante, Roger A Coulombe
The food-borne mycotoxin aflatoxin B₁ (AFB₁) poses a significant risk to poultry, which are highly susceptible to its hepatotoxic effects. Domesticated turkeys (Meleagris gallopavo) are especially sensitive, whereas wild turkeys (M. g. silvestris) are more resistant. AFB₁ toxicity entails bioactivation by hepatic cytochrome P450s to the electrophilic exo-AFB₁-8,9-epoxide (AFBO). Domesticated turkeys lack functional hepatic GST-mediated detoxification of AFBO, and this is largely responsible for the differences in resistance between turkey types...
January 13, 2018: Toxins
https://www.readbyqxmd.com/read/29342358/synthesis-and-biological-characterization-of-aryl-uracil-inhibitors-of-hepatitis-c-virus-ns5b-polymerase-discovery-of-abt-072-a-trans-stilbene-analog-with-good-oral-bioavailability
#4
John Randolph, A Chris Krueger, Pamela Donner, John K Pratt, Dachun Liu, Christopher E Motter, Todd W Rockway, Mike D Tufano, Rolf Wagner, Hock B Lim, Jill M Beyer, Rubina Mondal, Neeta S Panchal, Lynn Colletti, Yaya Liu, Gennadiy Koev, Warren M Kati, Lisa E Hernandez, David W A Beno, Kenton L Longenecker, Kent D Stewart, Emily O Dumas, Akhteruzzaman Molla, Clarence Maring
ABT-072 is a non-nucleoside HCV NS5B polymerase inhibitor that was discovered as part of a program to identify new direct-acting antivirals (DAAs) for the treatment of HCV infection. This compound was identified during a medicinal chemistry effort to improve on an original lead, inhibitor 1, which we described in a previous publication. Replacement of the amide linkage in 1 with a trans-olefin resulted in improved compound permeability and solubility, and provided much better pharmacokinetic properties in preclinical species...
January 17, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29339222/measurement-variability-of-liver-metastases-from-neuroendocrine-tumors-on-different-magnetic-resonance-imaging-sequences
#5
T Lestra, L Kanagaratnam, S Mulé, A Janvier, H Brixi, G Cadiot, A Dohan, C Hoeffel
PURPOSE: To assess dimension measurement variability of liver metastases from neuroendocrine tumors (LMNET) on different magnetic resonance imaging (MRI) sequences. MATERIAL AND METHODS: In this institutional review board-approved retrospective study from January 2011 to December 2012, all liver MRI examinations performed at our department in patients with at least one measurable LMNET according to response evaluation criteria in solid tumors (RECIST1.1) were included...
January 12, 2018: Diagnostic and Interventional Imaging
https://www.readbyqxmd.com/read/29338458/tenofovir-alafenamide-taf-treatment-of-hbv-what-are-the-unanswered-questions
#6
Mauro Viganò, Alessandro Loglio, Glenda Grossi, Pietro Lampertico
Tenofovir disoproxil fumarate (TDF), an ester prodrug of tenofovir (TFV), is one of the recommended drugs for chronic hepatitis B (CHB) patients. However, reduced kidney function and loss of bone mineral density have been reported in some CHB patients treated with TDF. Consequent to these safety issues, tenofovir alafenamide (TAF) [Vemlidy®], a phosphonate prodrug of TFV, was developed for the treatment of CHB patients. Areas covered: The favourable pharmacological profile of TAF allows a marked reduction in dosage (25 mg/day) thus reducing systemic exposure to tenofovir and improving the bone and renal safety, keeping however the same virological efficacy, compared to TDF 300 mg/day...
January 17, 2018: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/29337653/safety-and-immunogenicity-of-a-meningococcal-b-recombinant-vaccine-when-administered-with-routine-vaccines-to-healthy-infants-in-taiwan-a-phase-3-open-label-randomized-study
#7
Nan-Chang Chiu, Li-Min Huang, Arnold Willemsen, Chiranjiwi Bhusal, Ashwani Kumar Arora, Zenaida Reynoso Mojares, Daniela Toneatto
Neisseria meningitidis is associated with high mortality and morbidity in infants and children worldwide. This phase 3 study (NCT02173704) evaluated safety and immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine (4CMenB) co-administered with routine vaccines in Taiwanese infants. In total, 225 healthy infants were randomized (2:1) to receive 4CMenB and routine vaccines (4CMenB+Routine) or routine vaccines only (Routine group) at 2, 4, 6 and 12 months of age. Routine vaccines were diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b, 13-valent pneumococcal, hepatitis B, measles-mumps-rubella and varicella vaccines...
January 16, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29333947/persistence-of-hepatitis-b-immune-memory-until-9-10%C3%A2-years-of-age-following-hepatitis-b-vaccination-at-birth-and-dtap-ipv-hb-prp%C3%A2-t-vaccination-at-2-4-and-6-months
#8
Pope Kosalaraksa, Kulkanya Chokephaibulkit, Suwat Benjaponpitak, Chitsanu Pancharoen, Sunate Chuenkitmongkol, Siham B'Chir, Xavier Da Costa, Emmanuel Vidor
OBJECTIVE: To evaluate the long-term persistence of anti-hepatitis B surface (HBs) antibodies and the response to a HB challenge re-vaccination in children who had received a primary series of DTaP-IPV-HB-PRP∼T (Hexaxim™) or DTaP-IPV-HB/PRP∼T (Infanrix hexa™). METHODS: Two cohorts of participants who had previously received HB vaccine at birth followed by either DTaP-IPV-HB-PRP∼T or DTaP-IPV-HB/PRP∼T co-administered with PCV7 at 2, 4, 6 months of age in a randomized, Phase III, observer-blind study in Thailand, were followed up for anti-HBs antibodies (geometric mean concentrations [GMCs] and seroprotection [SP] rate [% of participants with a titer ≥10 mIU/mL]) at 12-18 months of age and 9-10 years of age...
January 15, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29327076/arms-down-cone-beam-ct-hepatic-angiography-performance-assessment-vascular-imaging-quality-and-imaging-artifacts
#9
Adrian J Gonzalez-Aguirre, Elena N Petre, Meier Hsu, Chaya S Moskowitz, Stephen B Solomon, Jeremy C Durack
INTRODUCTION: The practice of positioning patients' arms above the head during catheter-injected hepatic arterial phase cone beam CT (A-CBCT) imaging has been inherited from standard CT imaging due to image quality concerns, but interrupts workflow and extends procedure time. We sought to assess A-CBCT image quality and artifacts with arms extended above the head versus down by the side. METHODS: We performed an IRB approved retrospective evaluation of reformatted and 3D-volume rendered images from 91 consecutive A-CBCTs (43 arms up, 48 arms down) acquired during hepatic tumor arterial embolization procedures...
January 11, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29310928/sofosbuvir-and-velpatasvir-for-hepatitis-c-virus-infection-in-people-with-recent-injection-drug-use-simplify-an-open-label-single-arm-phase-4-multicentre-trial
#10
Jason Grebely, Olav Dalgard, Brian Conway, Evan B Cunningham, Philip Bruggmann, Behzad Hajarizadeh, Janaki Amin, Julie Bruneau, Margaret Hellard, Alain H Litwin, Philippa Marks, Sophie Quiene, Sharmila Siriragavan, Tanya L Applegate, Tracy Swan, Jude Byrne, Melanie Lacalamita, Adrian Dunlop, Gail V Matthews, Jeff Powis, David Shaw, Maria Christine Thurnheer, Martin Weltman, Ian Kronborg, Curtis Cooper, Jordan J Feld, Chris Fraser, John F Dillon, Phillip Read, Ed Gane, Gregory J Dore
BACKGROUND: Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to evaluate the efficacy of sofosbuvir and velpatasvir therapy in people with chronic HCV infection and recent injection drug use. METHODS: In this open-label, single-arm phase 4 trial (SIMPLIFY), we recruited participants with recent injection drug use (past 6 months) and chronic HCV genotype 1-6 infection from seven countries (19 sites)...
January 5, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29306503/a-mouse-model-with-age-dependent-immune-response-and-immune-tolerance-for-hbv-infection
#11
Xuerui Yi, Youcheng Yuan, Na Li, Lu Yi, Cuiling Wang, Ying Qi, Liang Gong, Guangze Liu, Xiangping Kong
BACKGROUND: Viral clearance of human HBV infection largely depends on the age of exposure. Thus, a mouse model with age-dependent immune response and immune-tolerance for HBV infection was established. METHODS: HBVRag1 mice were generated by crossing Rag1-/- mice with HBV-Tg mice. Following adoptive transfer of splenocytes adult (8-9 weeks old) and young (3 weeks old) HBVRag1 mice were named as HBVRag-ReA and HBVRag-ReY mice respectively. The biochemical parameters that were associated with viral load and immune function, as well as the histological evaluation of the liver tissues between the two mouse models were detected...
January 3, 2018: Vaccine
https://www.readbyqxmd.com/read/29300924/differentially-expressed-intrahepatic-genes-contribute-to-control-of-hepatitis-b-virus-replication-in-the-inactive-carrier-phase
#12
Hongyan Liu, Fahong Li, Xiaoyong Zhang, Jie Yu, Jinyu Wang, Jia Jia, Xueping Yu, Zhongliang Shen, Zhenghong Yuan, Xiaonan Zhang, Zhanqing Zhang, Xinxin Zhang, Lungen Lu, Hai Li, Mengji Lu, Jiming Zhang
Background: The natural history of chronic HBV infection was divided into four phases. Patients in the inactive carrier status (IC) and immune tolerant (IT) phase had normal ALT levels but huge different viral loads. The mechanism underlying low viral replication status in IC phase is unknown. Methods: We determined the intrahepatic transcriptomes of 83 chronic hepatitis B patients by microarray analysis of liver biopsies, and screened the effect of differentially regulated genes on HBV replication using specific siRNAs in vitro...
January 2, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29299370/safety-of-selective-internal-radiation-therapy-sirt-with-yttrium-90-microspheres-combined-with-systemic-anticancer-agents-expert-consensus
#13
REVIEW
Andrew Kennedy, Daniel B Brown, Jonas Feilchenfeldt, John Marshall, Harpreet Wasan, Marwan Fakih, Peter Gibbs, Alexander Knuth, Bruno Sangro, Michael C Soulen, Gianfranco Pittari, Ricky A Sharma
Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat inoperable primary or metastatic liver tumors. Eligible patients have usually been exposed to a variety of systemic anticancer therapies, including cytotoxic agents, targeted biologics, immunotherapy and peptide receptor radionuclide therapy (PRRT). All these treatments have potential interactions with SIRT; however, robust evidence on the safety of these potential combinations is lacking...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29289383/immunogenicity-of-a-two-dose-investigational-hepatitis-b-vaccine-hbsag-1018-using-a-toll-like-receptor-9-agonist-adjuvant-compared-with-a-licensed-hepatitis-b-vaccine-in-adults
#14
Sam Jackson, Joseph Lentino, James Kopp, Linda Murray, William Ellison, Margaret Rhee, Gerald Shockey, Lalith Akella, Kimberly Erby, William L Heyward, Robert S Janssen
BACKGROUND: Hepatitis B virus infection remains an important public health problem in the United States. Currently approved alum-adjuvanted vaccines require three doses and have reduced immunogenicity in adults, particularly in those who have diabetes mellitus, or are older, male, obese, or who smoke. METHODS: Phase 3 observer-blinded, randomized (2:1 HBsAg-1018 [HEPLISAV-B™]:HBsAg-Eng [Engerix-B®]), active-controlled trial in adults 18-70 years of age. HBsAg-1018 was administered intramuscularly at weeks 0 and 4 and placebo at week 24 and HBsAg-Eng at weeks 0, 4, and 24...
December 27, 2017: Vaccine
https://www.readbyqxmd.com/read/29285238/hepatitis-b-virus-hbv-x-gene-mutations-and-their-association-with-liver-disease-progression-in-hbv-infected-patients
#15
Ahmed A Al-Qahtani, Mashael R Al-Anazi, Nyla Nazir, Rohit Ghai, Ayman A Abdo, Faisal M Sanai, Waleed K Al-Hamoudi, Khalid A Alswat, Hamad I Al-Ashgar, Mohammed Q Khan, Ali Albenmousa, Damian Dela Cruz, Marie Fe F Bohol, Mohammed N Al-Ahdal
Hepatitis B virus (HBV) is one of the most widespread human pathogens causing chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). This study investigated the clinical impact of single and combinational mutations in HBx gene on the pathogenesis of HCC during progressive stages of liver disease. The patients were categorized into inactive HBV carriers, active carriers, cirrhosis and HCC groups based on disease severity. Male sex, age > 50 years, and high serum alanine aminotransferase level were associated with risk of progressive liver disease...
December 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/29280199/human-neonatal-fc-receptor-as-a-new-potential-antibody-binding-protein-for-antibody-immobilisation
#16
Woei Kean Ng, Theam Soon Lim, Ngit Shin Lai
A critical challenge in producing an antibody-based assay with the highest reproducibility and sensitivity is the strategy to immobilise antibodies to solid phase. To date, numerous methods of antibody immobilisation were reported but each was subjected to its advantages and limitations. The current study proposes a new potential antibody binding protein, the human neonatal Fc receptor. This protein has shown its high affinity to the Fc of antibody either in vivo or in vitro. Human neonatal Fc receptor is a heterodimer constructed by p51 α-heavy chain and β2-microglobulin light chain; however, the binding sites towards the antibody are located in the p51 α-heavy chain...
December 27, 2017: Biotechnology and Applied Biochemistry
https://www.readbyqxmd.com/read/29275303/effect-of-increased-intra-abdominal-pressure-on-liver-histology-and-hemodynamics-an-experimental-study
#17
Efstathios A Antoniou, Evi Kairi, Georgios A Margonis, Nikolaos Andreatos, Kazunari Sasaki, Christos Damaskos, Nikolaos Garmpis, Mario Samaha, Eriphyli Argyra, George Polymeneas, Matthew J Weiss, Timothy M Pawlik, Dionysios Voros, Gregory Kouraklis
BACKGROUND: While reduction of portal venous (PV) blood flow has been described in animal models of intra-abdominal hypertension, reports on compensatory changes in hepatic arterial (HA) flow, known as the hepatic arterial buffer response are controversial. MATERIALS AND METHODS: Pneumoperitoneum with helium was induced in 13 piglets. Hemodynamic measurements and pathological assessment were conducted at baseline and during the three subsequent phases: Phase A: 45 minutes with a stable intra-abdominal pressure of 25 mmHg; phase B: 45 minutes with a stable intra-abdominal pressure of 40 mmHg; and phase C during which the abdomen was re-explored and reperfusion of the liver was allowed to take place...
January 2018: In Vivo
https://www.readbyqxmd.com/read/29274193/efficacy-and-safety-of-6-or-8-weeks-of-simeprevir-daclatasvir-sofosbuvir-for-hcv-genotype-1-infection
#18
M S Sulkowski, J J Feld, E Lawitz, F Felizarta, A M Corregidor, O Khalid, R Ghalib, W B Smith, V Van Eygen, D Luo, L Vijgen, M Gamil, T N Kakuda, S Ouwerkerk-Mahadevan, P Van Remoortere, M Beumont
The phase 2, open-label ACCORDION (ClinicalTrials. gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (GT) 1 infection and either early-stage fibrosis or compensated cirrhosis. Patients were assigned to treatment groups according to their fibrosis stage. Early-stage fibrosis: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once daily for 6 weeks; compensated cirrhosis: same regimen for 8 weeks...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29262496/-safety-evaluation-of-10-%C3%AE-g-recombinant-hepatitis-b-vaccine-saccharomyces-cerecisiae-yeast-based-on-the-results-of-a-phase-of-%C3%A2-clinical-trial
#19
Y Zeng, J K Zhang, Y Tang, Z H Yang, J L Su, L Y Chen, Z H Huang, P Y Zeng, Z Y Jian, W M Du, M W Yang, T T Wang, F Z Wang, X F Liang, H Z Zheng
No abstract text is available yet for this article.
December 6, 2017: Zhonghua Yu Fang Yi Xue za Zhi [Chinese Journal of Preventive Medicine]
https://www.readbyqxmd.com/read/29246586/diagnostic-per-lesion-performance-of-a-simulated-gadoxetate-disodium-enhanced-abbreviated-mri-protocol-for-hepatocellular-carcinoma-screening
#20
B G Tillman, J D Gorman, J M Hru, M H Lee, M C King, C B Sirlin, R M Marks
AIM: To evaluate the diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI (AMRI) in cirrhotic and chronic hepatitis B (CHB) patients for hepatocellular carcinoma (HCC) screening. MATERIALS AND METHODS: Seventy-nine consecutive patients at risk for HCC due to cirrhosis and/or CHB were included in this retrospective study. For each patient, the first gadoxetate disodium-enhanced MRI between 2008 through 2014 was analysed. Two independent readers read an anonymised abbreviated image set comprising axial T1-weighted (W) images with fat saturation in the hepatobiliary phase, 20 minutes or more after gadoxetate injection, and axial T2W single-shot fast spin echo images...
December 12, 2017: Clinical Radiology
keyword
keyword
71570
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"